- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07224581
Beeline: En fase 3-studie i GRIN-relatert nevro-utviklingsforstyrrelse
En multinasjonal, multicenter-studie med en åpen fase 1b og en randomisert, dobbeltblind, placebo-kontrollert fase 3 etterfulgt av en åpen forlengelse for å vurdere effekt, sikkerhet, tolerabilitet og farmakokinetikk av Radiprodil hos deltakere med GRIN-relatert nevro-utviklingsforstyrrelse
The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant.
This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort).
Participants in each cohort will be randomized 1:1 to receive active drug (radiprodil) or matching placebo (Part A). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.
The placebo-controlled portion is expected to be approximately 16 weeks for participants in Phase 3 Cohort 1 and 28 weeks for participants in Phase 3 Cohort 2.
The study will evaluate the effect of radiprodil on seizures and non-seizure symptoms and assess safety.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Participants are assigned in a 1:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Open-Label Extension, Part B. The dosing regimen includes a fixed titration schedule over 4 weeks.
This study is divided into the following parts:
Part A: Randomized, double-blind, placebo-controlled
- Screening/Observation Period: To assess eligibility
- Titration Period (approximately 4 weeks): Titration of radiprodil or placebo to target dose
- Maintenance Period (Part A): Target dose of radiprodil or placebo maintained for 12 weeks (Phase 3 Cohort 1) or 24 weeks (Phase 3 Cohort 2)
- Tapering and Follow-up Period: Gradual decrease and Follow-up Period for participants not entering Part B
Part B: Open-label safety follow-up period
- Open-Label Treatment Period: Participants will continue to receive radiprodil until such time as either the participant withdraws/is withdrawn from the study, sponsor terminates the study, or market access is available
- Tapering and Follow-up Period: Gradual decrease and follow-up observation period for participants upon leaving the study
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Operations
- Telefonnummer: +1-877-225-0014
- E-post: ClinicalTrials@GrinTherapeutics.com
Studiesteder
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Rekruttering
- Queensland Children's Hospital
-
Hovedetterforsker:
- Catherine Riney
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Rekruttering
- Austin Health
-
Hovedetterforsker:
- Ingrid Scheffer
-
-
-
-
-
Brussels, Belgia, 1090
- Rekruttering
- UZ Brussel
-
Ta kontakt med:
- Ine Hoogwijs
- E-post: ine.hoogwijs@uzbrussel.be
-
Ta kontakt med:
- Yentse Caeyers
- E-post: yentse.caeyers@uzbrussel.be
-
Hovedetterforsker:
- Ine Hoogwijs
-
Edegem, Belgia, 2650
- Rekruttering
- University Hospital Antwerp
-
Hovedetterforsker:
- Matthias de Wachter, MD
-
-
-
-
California
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- UCLA Health - Ronald Reagan UCLA Medical Center
-
Ta kontakt med:
- Angela Martinez
- Telefonnummer: 310-968-8942
- E-post: AngelaMartinez@mednet.ucla.edu
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- Lucile Packard Children's Hospital
-
Ta kontakt med:
- Telefonnummer: 650-721-1458
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- Children's Hospital Colorado - Anschutz Medical Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- Children's National Medical Center
-
Hovedetterforsker:
- John Schreiber, MD
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- Children's National Hospital
-
Ta kontakt med:
- Chloe Hooker
- Telefonnummer: 202-476-4809
- E-post: chooker@childrensnational.org
-
-
Florida
-
Miami, Florida, Forente stater, 33155
- Rekruttering
- Nicklaus Children's Hospital
-
Ta kontakt med:
- Dainelys Pena Rodriquez
- Telefonnummer: 786-624-3547
- E-post: dainelys.penarodriguez@nicklaushealth.org
-
Winter Park, Florida, Forente stater, 32789
- Rekruttering
- Pediatric Neurology and Epilepsy
-
Ta kontakt med:
- Denise Hubert
- Telefonnummer: 407-293-1122
- E-post: dhubert@pediatricneurologyandepilepsy.com
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- Iowa Health Care - Pediatric Neurology & Specialty Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Boston Children's Hospital
-
Ta kontakt med:
- Helen Olson
- E-post: Helen.Olson@childrens.harvard.edu
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- Northeast Regional Epilepsy Group (NEREG) - Hackensack
-
Ta kontakt med:
- Hardik A Rana, MBBS
- Telefonnummer: 551-497-5000
- E-post: hrana@epilepsygroup.com
-
-
New York
-
New York, New York, Forente stater, 10032
- Rekruttering
- Columbia University - Harkness
-
Ta kontakt med:
- Jaimie Gowatsky
- Telefonnummer: 917-838-6514
- E-post: jg2917@cumc.columbia.edu
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University Health System
-
Hovedetterforsker:
- Muhammad Zafar, MD
-
Durham, North Carolina, Forente stater, 27705
- Rekruttering
- Duke Health-Duke Children's Hospital & Health Center
-
Ta kontakt med:
- Gloria Pinero
- Telefonnummer: 919-613-0767
- E-post: gloria.pinero@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Hovedetterforsker:
- Kelly Kremer, MD
-
Cincinnati, Ohio, Forente stater, 45229
- Har ikke rekruttert ennå
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Ta kontakt med:
- Jennie Minnick
- E-post: MINNICK@chop.edu
-
-
Texas
-
Austin, Texas, Forente stater, 78757
- Rekruttering
- Child Neurology Consultants of Austin - South Austin
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- The University of Texas Southwestern Medical Center (UTSW)
-
Dallas, Texas, Forente stater, 75207
- Rekruttering
- Children's Health Specialty Center, Dallas
-
Hovedetterforsker:
- Charuta Joshi, MD
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- UTHealth Houston
-
Ta kontakt med:
- Annette Frenk, MSc
- Telefonnummer: 713-500-7164
- E-post: Annette.C.FrenkOquendo@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Seattle Children's Hospital
-
-
-
-
-
Angers, Frankrike, 49933
- Rekruttering
- CHU Angers
-
Hovedetterforsker:
- Patrick van Bogaert, MD
-
Angers, Frankrike, 49933
- Rekruttering
- Centre Hospitalier Universitaire d'Angers (CHU Angers)
-
Ta kontakt med:
- Patrick Van Bogaert
- E-post: Patrick.VanBogaert@chu-angers.fr
-
Hovedetterforsker:
- Patrick Van Bogaert
-
Bron, Frankrike, 69500
- Rekruttering
- Hospices Civils de Lyon
-
Hovedetterforsker:
- Eleni Panagiotakaki, MD, PhD
-
Bron, Frankrike, 69677
- Rekruttering
- Hospices Civils De Lyon
-
Ta kontakt med:
- Eleni Panagiotakaki
- E-post: eleni.panagiotakaki@chu-lyon.fr
-
Ta kontakt med:
- Lea Barbieri
- E-post: lea.barbieri01@chu-lyon.fr
-
Hovedetterforsker:
- Eleni Panagiotakaki
-
Dijon, Frankrike, 21079
- Rekruttering
- CHU de Dijon
-
Hovedetterforsker:
- Benoit Mazel, MD
-
Marseille, Frankrike, 13005
- Rekruttering
- AP HM Hopital d'enfants de la Timone
-
Hovedetterforsker:
- Mathieu Milh, MD, PhD
-
Paris, Frankrike, 75015
- Rekruttering
- Hopital Necker Enfants Malades (APHP)
-
Hovedetterforsker:
- Rima El Nabbout, MD, PhD
-
Paris, Frankrike, 75743
- Rekruttering
- Hôpital Necker Enfants Malades
-
Ta kontakt med:
- Michaela Semeraro
- E-post: michaela.semeraro@aphp.fr
-
Ta kontakt med:
- Rima Nabbout
- E-post: rima.nabbout@aphp.fr
-
Hovedetterforsker:
- Rima Nabbout
-
Toulouse, Frankrike, 31059
- Rekruttering
- Hopital des Enfants ; CHU Toulouse
-
Hovedetterforsker:
- Caroline Hachon Le Camus, MD
-
Toulouse, Frankrike, Cedex 9
- Rekruttering
- CHU Toulouse - Hôpital Purpan
-
Ta kontakt med:
- Caroline Hachon Le Camus
- E-post: hachonlecamus.c@chu-toulouse.fr
-
Hovedetterforsker:
- Caroline Hachon Le Camus
-
-
-
-
-
Bologna, Italia, 40139
- Rekruttering
- Azienda Unita Sanitaria Locale Di Bologna, IRCCS lstituto Delle Scienze Neurologiche
-
Hovedetterforsker:
- Luca Soliani Soliani, MD
-
Milan, Italia, 20133
- Rekruttering
- Fondazione IRCCS lstituto Neurologico Carlo Besta
-
Hovedetterforsker:
- Francesca Ragona, MD
-
Pavia, Italia
- Rekruttering
- IRCCS Fondazione Istituto Neurologico Nazionale Casimiro Mondino
-
Hovedetterforsker:
- Valentina De Giorgis
-
Ta kontakt med:
- Valentina De Giorgis
- E-post: valentina.degiorgis@mondino.it
-
Pavia, Italia, 27100
- Rekruttering
- Fondazione lstituto Neurologico Nazionale Casimiro Mondino
-
Ta kontakt med:
- MD, PhD
-
Hovedetterforsker:
- Valentina De Giorgis, MD, PhD
-
Roma, Italia, 00165
- Rekruttering
- Ospedale Pediatrico Bambino Gesu
-
Hovedetterforsker:
- Nicola Specchio
-
Ta kontakt med:
- Nicola Specchio
- E-post: nicola.specchio@opbg.net
-
Ta kontakt med:
- Nicola Pietrafusa
- E-post: nicola1.pietrafusa@opbg.net
-
Underetterforsker:
- Nicola Pietrafusa
-
-
Viale Pieraccini
-
Florence, Viale Pieraccini, Italia, 24
- Rekruttering
- Azienda Ospedaliera Universitaria Meyer IRCCS
-
Hovedetterforsker:
- Renzo Guerrini
-
Ta kontakt med:
- Renzo Guerrini
- E-post: r.guerrini@meyer.it
-
-
-
-
-
Minami, Japan
- Rekruttering
- Kanagawa Children's Medical Center
-
Hovedetterforsker:
- Tomohide Goto, MD
-
Miyazaki, Japan
- Rekruttering
- University of Miyazaki Hospital
-
Hovedetterforsker:
- Yasuhiro Kimoto, MD
-
Nagoya, Japan
- Rekruttering
- Nagoya University Hospital
-
Hovedetterforsker:
- Hiroyuki Kidokoro, MD
-
Niigata, Japan
- Rekruttering
- National Hospital Organization Nishiniigata Chuo Hospital
-
Hovedetterforsker:
- Yu Kobayashi, MD
-
Osaka, Japan, 534-0021
- Rekruttering
- Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital
-
Hovedetterforsker:
- Shin Okazaki, MD
-
Shibukawa, Japan
- Rekruttering
- Showa Medical University Hospital
-
Hovedetterforsker:
- Mitsuhiro Kato, MD
-
-
-
-
South Holland
-
Rotterdam, South Holland, Nederland
- Rekruttering
- Erasmus MC (Erasmus Universitair Medisch Centrum Rotterdam)
-
Ta kontakt med:
- Danielle Veenma
- E-post: d.veenma@erasmusmc.nl
-
Ta kontakt med:
- E-post: Grin.encore@erasmusmc.nl
-
Hovedetterforsker:
- Danielle Veenma
-
Underetterforsker:
- Suzanna Koudijs
-
-
-
-
-
Lodz, Polen, 93-338
- Rekruttering
- Institute of Polish Mother's Health Center (Instytut Centrum Zdrowia Matki Polki)
-
Hovedetterforsker:
- Lukasz Przyslo
-
Ta kontakt med:
- Lukasz Przyslo
- E-post: lukasz.przyslo@iczmp.edu.pl
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 04-730
- Rekruttering
- lnstytut Pomnik Centrum Zrowia Dziecka
-
Hovedetterforsker:
- Sergiusz Jozwiak, MD, PhD
-
-
-
-
-
Ljubljana, Slovenia, 1525
- Rekruttering
- University Children's Hospital
-
Hovedetterforsker:
- Damjan Osredkar
-
Ta kontakt med:
- Damjan Osredkar
- E-post: damjan.osredkar@kclj.si
-
Ta kontakt med:
- Nika Košir
- E-post: nika.kosir@kclj.si
-
-
-
-
-
Madrid, Spania, 28009
- Rekruttering
- Hospital Universitario Infantil Nino Jesus
-
Hovedetterforsker:
- Victor Soto Insuga, MD
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spania
- Rekruttering
- Hospital Sant Joan de Deus
-
Hovedetterforsker:
- Angeles Garcia Cazorla
-
Ta kontakt med:
- Angeles Garcia Cazorla
- E-post: angeles.garcia@sjd.es
-
Ta kontakt med:
- Juan Lascano Nazareno
- E-post: nazarenojuan.lascano@sjd.es
-
Underetterforsker:
- Juan Lascano Nazareno
-
-
-
-
-
Glasgow, Storbritannia
- Rekruttering
- Royal Hospital for Children Glasgow
-
Hovedetterforsker:
- Sameer Zuberi
-
Ta kontakt med:
- Sameer Zuberi
- E-post: sameer.zuberi@ggc.scot.nhs.uk
-
London, Storbritannia, G51 4TF
- Rekruttering
- Great Ormond Street Hospital For Children NHS Foundation Trust
-
Ta kontakt med:
- Amy McTague, MD
- E-post: a.mctague@ucl.ac.uk
-
Hovedetterforsker:
- Amy McTague, MD
-
London, Storbritannia, Wc1N 3JH
- Rekruttering
- Great Ormond Street Hospital for Children NHS Foundation
-
Hovedetterforsker:
- Amy McTague, MBChB, MRCPCH, PhD
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Storbritannia
- Rekruttering
- Sheffield Children's Hospital NHS Foundation Trust
-
Ta kontakt med:
- Archana Desurkar
- E-post: archana.desurkar@sch.nhs.uk
-
Hovedetterforsker:
- Archana Desurkar
-
-
-
-
-
Seoul, Sør -Korea, 03080
- Rekruttering
- Seoul National University Hospital
-
Hovedetterforsker:
- Jong-Hee Chae, MD, PhD
-
-
-
-
-
Bielefeld, Tyskland, 33617
- Rekruttering
- Universitatsklinikum OWL der Universitat Bielefeld
-
Hovedetterforsker:
- Tilman Polster, MD
-
Greifswald, Tyskland
- Rekruttering
- Universitatsmedizin Greifswald Klinik und Poliklinik fur Frauenheilkunde und Geburtshilfe
-
Ta kontakt med:
- Astrid Bertsche
- E-post: astrid.bertsche@med.uni-greifswald.de
-
Hovedetterforsker:
- Astrid Bertsche
-
Leipzig, Tyskland, 04103
- Rekruttering
- Klinik und Policlinik fur Kinder - und Jugendmedizin
-
Ta kontakt med:
- Andreas Merkenschlager
- E-post: Andreas.Merkenschlager@medizin.uni-leipzig.de
-
Ta kontakt med:
-
Hovedetterforsker:
- Andreas Merkenschlager
-
-
Saxony
-
Leipzig, Saxony, Tyskland, 04103
- Rekruttering
- Universitatsklinikum Leipzig
-
Hovedetterforsker:
- Andreas Merkenschlager, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Part A, Participant:
- Diagnosed with GRIN-NDD with GRIN1, GRIN2A, GRIN2B, or GRIN2D gene variants known to result in GoF of the NMDA receptor
- Phase 3 Cohort 1 (Qualifying Seizures Cohort) ONLY: Experiencing at least 1 CMS per week and ≥4 CMS (generalized or focal) during screening
- With history of inadequate response to at least 2 standard antiseizure medications (ASMs)
- Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort) ONLY: With significant neurodevelopmental symptoms and a GRIN-CGI-S score ≥4
- On a stable dose of standard ASMs for at least 4 weeks prior to screening and should remain on stable doses throughout study participation
- On stable nonpharmacological treatments such as ketogenic diet and should remain stable throughout study participation
Part B:
- Participant has completed Part A and is eligible to continue study participation according to the judgement of the investigator and sponsor.
Exclusion Criteria:
PART A, Participant:
- Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation or study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
- Is receiving >4 standard ASMs at screening
- Has a body weight of less than 5 kg at screening
Part B:
- Participant has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Radiprodil
Liquid suspension of radiprodil, at varying concentrations depending on participant's weight. The following dose-escalation regimen (twice daily [BID]) will be used: Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose. |
Radiprodil oral suspension |
|
Placebo komparator: Placebo
Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen. |
Placebo-to-match radiprodil oral suspension |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Del A - Fase 3 Kohort 1 (Kvalifiserende Anfall Kohort): Tellbare motoriske anfall (CMS)
Tidsramme: 12 uker
|
12 uker
|
|
Del A - Fase 3 Kohort 2 (Uten kvalifiserende anfall hjelpekohort): Bivirkninger (AEs), alvorlige bivirkninger (SAEs) og legemiddelbivirkninger (ADRs)
Tidsramme: 24 uker
|
24 uker
|
|
Del B - Åpen merkeutvidelse: Bivirkninger (AEs), alvorlige bivirkninger (SAEs) og legemiddelbivirkninger (ADRs)
Tidsramme: Gjennomsnitt på 2 år
|
Gjennomsnitt på 2 år
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Del A - Fase 3 Kohort 1 (Kvalifiserende Anfallskohort): Andel deltakere med ≥50 % reduksjon i CMS
Tidsramme: 12 uker
|
12 uker
|
|
Del A - Fase 3 Kohort 1 (Kvalifiserende Anfall Kohort): CMS-frie dager
Tidsramme: 12 uker
|
12 uker
|
|
Del A - Fase 3 Kohort 1 (Kvalifiserende Anfall Kohort): GRIN-NDD-spesifikk Clinical Global Impression - Endring [CGI-C] skala
Tidsramme: 12 uker
|
12 uker
|
|
Del A - Fase 3 Kull 1 (Kvalifiserende Anfall Kull): Aberrant Atferdsliste-Samfunn (ABC-2C) irritabilitets subskala
Tidsramme: 12 uker
|
12 uker
|
|
Del A - Fase 3 Kohort 1 (Kvalifiserende anfallskohort): Vineland Adaptive Behavior Scale 3. utgave (VABS-3) dagligliv personlig underdomene
Tidsramme: 12 uker
|
12 uker
|
|
Del A - Fase 3 Kohort 2 (Uten kvalifiserende anfall hjelpekohort): GRIN-CGI-C skala
Tidsramme: 24 uker
|
24 uker
|
|
Del A - Fase 3 Kohort 2 (Uten kvalifiserende anfallshjelpekohort): ABC-2C irritabilitets subskala
Tidsramme: 24 uker
|
24 uker
|
|
Del A - Fase 3 Kull 2 (Uten kvalifiserende anfall hjelpekull): VABS-3 dagligliv personlig subdomene
Tidsramme: 24 uker
|
24 uker
|
|
DEL B - Åpen merkeutvidelse: CMS-frekvens
Tidsramme: gjennomsnittlig 2 år
|
gjennomsnittlig 2 år
|
|
DEL B - Åpen merkeutvidelse: CMS-frie dager
Tidsramme: gjennomsnittlig 2 år
|
gjennomsnittlig 2 år
|
|
DEL B - Åpen merkeutvidelse: ABC-2C irritabilitetsskala
Tidsramme: gjennomsnitt på 2 år
|
gjennomsnitt på 2 år
|
|
DEL B - Åpen merkeutvidelse: VABS-3 dagligliv personlig underdomene poengsum
Tidsramme: gjennomsnittlig 2 år
|
gjennomsnittlig 2 år
|
|
DEL B - Åpen merkeutvidelse: GRIN-CGI-C skala
Tidsramme: gjennomsnittlig 2 år
|
gjennomsnittlig 2 år
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Russell Chin, GRIN Therapeutics, Inc.
- Studieleder: Stephen Tisi, GRIN Therapeutics, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Beeline RAD-GRIN-101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .